First Time Loading...

Cullinan Oncology Inc
NASDAQ:CGEM

Watchlist Manager
Cullinan Oncology Inc Logo
Cullinan Oncology Inc
NASDAQ:CGEM
Watchlist
Price: 17.04 USD -3.89% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of CGEM.

Key Points:
CGEM Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Cullinan Oncology Inc's business.

What risks and challenges
does Cullinan Oncology Inc face in the near future?

Summarize the latest earnings report
of Cullinan Oncology Inc.

Provide P/E
for Cullinan Oncology Inc and its competitors.

Financials

Balance Sheet Decomposition
Cullinan Oncology Inc

Current Assets 480.2m
Cash & Short-Term Investments 467.1m
Other Current Assets 13.1m
Non-Current Assets 4m
PP&E 3.5m
Other Non-Current Assets 459k
Current Liabilities 28.1m
Accounts Payable 2.5m
Accrued Liabilities 25.6m
Non-Current Liabilities 2.3m
Other Non-Current Liabilities 2.3m
Efficiency

Earnings Waterfall
Cullinan Oncology Inc

Revenue
0 USD
Operating Expenses
-190.6m USD
Operating Income
-190.6m USD
Other Expenses
37.5m USD
Net Income
-153.2m USD

Free Cash Flow Analysis
Cullinan Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CGEM Profitability Score
Profitability Due Diligence

Cullinan Oncology Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

20/100
Profitability
Score

Cullinan Oncology Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

CGEM Solvency Score
Solvency Due Diligence

Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGEM Price Targets Summary
Cullinan Oncology Inc

Wall Street analysts forecast CGEM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGEM is 26.01 USD with a low forecast of 19.19 USD and a high forecast of 35.7 USD.

Lowest
Price Target
19.19 USD
13% Upside
Average
Price Target
26.01 USD
53% Upside
Highest
Price Target
35.7 USD
110% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CGEM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CGEM Price
Cullinan Oncology Inc

1M 1M
-8%
6M 6M
+88%
1Y 1Y
+58%
3Y 3Y
-55%
5Y 5Y
-43%
10Y 10Y
-43%
Annual Price Range
17.04
52w Low
7.89
52w High
19.02
Price Metrics
Average Annual Return -40.05%
Standard Deviation of Annual Returns 6.82%
Max Drawdown -86%
Shares Statistics
Market Capitalization 731m USD
Shares Outstanding 43 065 600
Percentage of Shares Shorted 2.01%

CGEM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cullinan Oncology Inc Logo
Cullinan Oncology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

731m USD

Dividend Yield

0%

Description

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Contact

MASSACHUSETTS
Cambridge
One Main Street, Suite 520
+16174104650.0

IPO

2021-01-08

Employees

31

Officers

President, CEO & Director
Mr. Nadim Ahmed
Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Dr. Patrick A. Baeuerle Ph.D.
CFO & Treasurer
Mr. Jeffrey Trigilio
Chief Scientific Officer
Dr. Jennifer Michaelson Ph.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Jacquelyn L. Sumer J.D.
Senior Vice President of Communications
Ms. Rose Weldon
Show More
Chief Human Resources Officer
Mr. Steve Andre
Chief Business Officer
Dr. Corinne Savill Ph.D.
Chief Medical Officer
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.
Chief Technical Operations Officer
Mr. Kevin A. Johnston
Show Less

See Also

Discover More